- Home
- DRCT vs VIVS Comparison
DRCT vs VIVS Comparison
Compare DRCT & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DRCT | VIVS |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 8.1M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | DRCT | VIVS |
|---|---|---|
| Price | $4.10 | $1.90 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $330.00 | N/A |
| AVG Volume (30 Days) | ★ 7.2M | 36.4K |
| Earning Date | 11-06-2025 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,369,000.00 | $140,000.00 |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | $25.40 | $15.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 35.92 |
| 52 Week Low | $1.58 | $1.41 |
| 52 Week High | $80.85 | $21.96 |
Technical Indicators
Market Signals| Indicator | DRCT | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 90.17 | 44.41 |
| Support Level | $1.58 | $1.98 |
| Resistance Level | $2.98 | $2.18 |
| Average True Range (ATR) | 0.44 | 0.15 |
| MACD | 0.29 | 0.01 |
| Stochastic Oscillator | 70.16 | 14.29 |
Price Performance
Historical ComparisonAbout DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
About VIVS VivoSim Labs Inc.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.